文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌的每周超大分割放疗

Weekly ultra-hypofractionated radiotherapy in localised prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-05-26

本研究回顾性分析了2010至2015年接受每周超大分割放疗(36 Gy分6次每周照射)的140例非转移性局限性前列腺癌患者,其中86%为高危疾病。中位随访52个月,全组中位无进展生存期和总生存期分别为70个月和72个月;放疗时激素敏感患者的中位总生存期为75个月,去势抵抗患者的中位无进展生存期和总生存期分别为20个月和61个月。作者认为该方案可作为无法每日治疗或无法接受立体定向体部放疗患者的一种选择。

要点

  • 每周超大分割放疗方案为前列腺照射36 Gy分6次每周照射。
  • 140例患者中86%为高危,31%为Gleason分级分组4或5,48%为T3期或更高。
  • 全组中位无进展生存期70个月,中位总生存期72个月,中位随访52个月。

核心结论

  • 作者认为,每周超大分割放疗方案可作为无法每日治疗或无法接受立体定向体部放疗患者的一种选择。

研究设计与样本

  • 本研究为回顾性分析,纳入2010至2015年接受每周超大分割放疗方案(前列腺36 Gy分6次每周照射)的所有非转移性局限性前列腺癌患者,共140例。

主要发现

  • 140例患者中86%为高危疾病,31%为Gleason分级分组4或5,48%为T3期或更高。
  • 所有患者均接受激素治疗,从开始激素治疗到开始放疗的中位间隔为11个月,34%的患者在开始放疗前已进展为非转移性去势抵抗性疾病。
  • 中位随访52个月,全组中位无进展生存期为70个月,中位总生存期为72个月。
  • 放疗时激素敏感患者的中位无进展生存期未达到,中位总生存期为75个月;放疗时去势抵抗患者的中位无进展生存期为20个月,中位总生存期为61个月。

临床怎么用

  • 本研究中心(The Royal Marsden Hospital NHS Foundation Trust)的做法是,对无法或不愿每日前往放疗科且无法获得或不适合立体定向体部放疗的患者,提供每周超大分割放疗方案(前列腺36 Gy分6次每周照射)。
  • 作者认为,该每周超大分割放疗方案可作为无法每日治疗或无法接受立体定向体部放疗患者的一种选择。

局限性

  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderately hypofractionated radiotherapy regimens or stereotactic body radiotherapy (SBRT) are standard of care for localised prostate cancer. However, some patients are unable or unwilling to travel daily to the radiotherapy department and do not have access to, or are not candidates for, SBRT. For many years, The Royal Marsden Hospital NHS Foundation Trust has offered a weekly ultra-hypofractionated radiotherapy regimen to the prostate (36 Gy in 6 weekly fractions) to patients unable/unwilling to travel daily. METHODS: The current study is a retrospective analysis of all patients with non-metastatic localised prostate cancer receiving this treatment schedule from 2010 to 2015. RESULTS: A total of 140 patients were included in the analysis, of whom 86 % presented with high risk disease, with 31 % having Gleason Grade Group 4 or 5 disease and 48 % T3 disease or higher. All patients received hormone treatment, and there was often a long interval between start of hormone treatment and start of radiotherapy (median of 11 months), with 34 % of all patients having progressed to non-metastatic castrate-resistant disease prior to start of radiotherapy. Median follow-up was 52 months. Median progression-free survival (PFS) and overall survival (OS) for the whole group was 70 months and 72 months, respectively. PFS and OS in patients with hormone-sensitive disease at time of radiotherapy was not reached and 75 months, respectively; and in patients with castrate-resistant disease at time of radiotherapy it was 20 months and 61 months, respectively. CONCLUSION: Our data shows that a weekly ultra-hypofractionated radiotherapy regimen for prostate cancer could be an option in those patients for whom daily treatment or SBRT is not an option.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sundahl N, Brand D, Parker C, et al. Weekly ultra-hypofractionated radiotherapy in localised prostate cancer. Clin Transl Radiat Oncol. 2024. PMID: 38872938. doi:10.1016/j.ctro.2024.100800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。